Clinicopathological and prognostic significance of S100A4 overexpression in colorectal cancer: a meta-analysis

Diagnostic Pathology

Shan Li²  Xue Qin²  Yu He²  Taijie Li²  Li Xie²  Jian Wang²  Weizhong Tang¹  Yanqiong Liu² 

[1] Department of Colorectal and Anal Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China;Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China

关键词: S100A4;    Prognosis;    Progression;    Meta-analysis;    Colorectal cancer;   

Others  :  866216
DOI  :  10.1186/1746-1596-8-181

 received in 2013-09-04, accepted in 2013-10-21,  发布年份 2013

【 摘 要 】

Background

Accumulated evidence has indicated a correlation between S100A4 expression and colorectal cancer (CRC) progression. However, its prognostic significance for patients with CRC remains inconclusive. To clarify their relationship, a meta-analysis of the relevant published studies was performed.

Method

PubMed, Cochrane Library, and Web of Science databases were electronically searched. All studies evaluating the prognostic value of S100A4 expression in CRC patients regarding survival and a series of clinicopathological parameters were included. The effect of S100A4 expression on the overall survival (OS) and disease-free survival (DFS) were measured by pooled hazard ratios (HRs) and 95% confidence intervals (CIs), while the effect of S100A4 expression on the clinicopathological parameters were measured by the pooled odds ratios (ORs) and their 95% CIs.

Results

Eleven studies (2,824 patients in total) were included in the meta-analysis. Overall, S100A4 overexpression was significantly associated with worse OS (HR = 1.90, 95% CI: 1.58–2.29, P <0.001), and worse DFS (HR = 2.16, 95% CI: 1.53–3.05, P <0.001) in patients with CRC. Subgroup analyses showed that S100A4 overexpression was significantly correlated with poor OS in Asian, European, and Australian patients and patients treated with surgery or chemotherapy. Additionally, there were significant associations between S100A4 expression and several clinicopathological parameters (tumour location, lymph node metastasis, nodal status, TNM stage, and tumour depth).

Conclusions

This meta-analysis indicates that S100A4 overexpression seems to correlate with tumour progression and poor prognosis of CRC patients. It may be a useful marker to predict progression and prognosis of CRC.

Virtual slides

The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/8643820431072915 webcite

【 授权许可】

   
2013 Liu et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, Jemal A, Schymura MJ, Lansdorp-Vogelaar I, Seeff LC, et al.: Annual report to the nation on the status of cancer, 1975–2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 2010, 116(3):544-573.
• [2]Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F: Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer (Oxford, England: 1990) 2012, 49(6):1374-1403.
• [3]Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. Cancer J Clin 2013, 63(1):11-30.
• [4]Sung JJ, Lau JY, Goh KL, Leung WK, Asia Pacific Working Group on Colorectal Cancer: Increasing incidence of colorectal cancer in Asia: implications for screening. Lancet Oncol 2005, 6(11):871-876.
• [5]Boghossian S, Hawash A: Chemoprevention in colorectal cancer–where we stand and what we have learned from twenty year's experience. Surgeon 2012, 10(1):43-52.
• [6]O'Connell JB, Maggard MA, Ko CY: Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004, 96(19):1420-1425.
• [7]Christofori G: New signals from the invasive front. Nature 2006, 441(7092):444-450.
• [8]Stein U, Schlag PM: Clinical, biological, and molecular aspects of metastasis in colorectal cancer. Recent Results Cancer Res 2007, 176:61-80.
• [9]Garrett SC, Varney KM, Weber DJ, Bresnick AR: S100A4, a mediator of metastasis. J Biol Chem 2006, 281(2):677-680.
• [10]Mishra SK, Siddique HR, Saleem M: S100A4 calcium-binding protein is key player in tumor progression and metastasis: preclinical and clinical evidence. Cancer Metastasis Rev 2012, 31(1–2):163-172.
• [11]Sagara Y, Miyata Y, Iwata T, Kanda S, Hayashi T, Sakai H, Kanetake H: Clinical significance and prognostic value of S100A4 and matrix metalloproteinase-14 in patients with organ-confined bladder cancer. Exp Ther Med 2010, 1(1):27-31.
• [12]de Silva RS, Martin L, Roshanlall C, Winstanley J, Leinster S, Platt-Higgins A, Carroll J, West C, Barraclough R, Rudland P: Association of S100A4 and osteopontin with specific prognostic factors and survival of patients with minimally invasive breast cancer. Clin Cancer Res 2006, 12(4):1192-1200.
• [13]Ninomiya I, Ohta T, Fushida S, Endo Y, Hashimoto T, Yagi M, Fujimura T, Nishimura G, Tani T, Shimizu K, et al.: Increased expression of S100A4 and its prognostic significance in esophageal squamous cell carcinoma. Int J Oncol 2001, 18(4):715-720.
• [14]Li H, Liu ZQ, Xu CX, Chen YY, Zhang JW, Cui B, Chen XW, An GH, She XJ, Liu HT, et al.: Overexpression of S100A4 is closely associated with the progression and prognosis of gastric cancer in young patients. Oncol Lett 2013, 5(5):1485-1490.
• [15]Tsuna M, Kageyama SI, Fukuoka J, Kitano H, Doki Y, Tezuka H, Yasuda H: Significance of S100A4 as a prognostic marker of lung squamous cell carcinoma. Anticancer Res 2009, 29(7):2547-2554.
• [16]Ikenaga N, Ohuchida K, Mizumoto K, Yu J, Fujita H, Nakata K, Ueda J, Sato N, Nagai E, Tanaka M: S100A4 mRNA is a diagnostic and prognostic marker in pancreatic carcinoma. J Gastrointest Surg 2009, 13(10):1852-1858.
• [17]Gongoll S, Peters G, Mengel M, Piso P, Klempnauer J, Kreipe H, von Wasielewski R: Prognostic significance of calcium-binding protein S100A4 in colorectal cancer. Gastroenterology 2002, 123(5):1478-1484.
• [18]Cho YG, Kim CJ, Nam SW, Yoon SH, Lee SH, Yoo NJ, Lee JY, Park WS: Overexpression of S100A4 is closely associated with progression of colorectal cancer. World J Gastroenterol 2005, 11(31):4852-4856.
• [19]Hemandas AK, Salto-Tellez M, Maricar SH, Leong AF, Leow CK: Metastasis-associated protein S100A4–a potential prognostic marker for colorectal cancer. J Surg Oncol 2006, 93(6):498-503.
• [20]Kim JH, Kim CN, Kim SY, Lee JS, Cho D, Kim JW, Yoon SY: Enhanced S100A4 protein expression is clinicopathologically significant to metastatic potential and p53 dysfunction in colorectal cancer. Oncol Rep 2009, 22(1):41-47.
• [21]Boye K, Nesland JM, Sandstad B, Maelandsmo GM, Flatmark K: Nuclear S100A4 is a novel prognostic marker in colorectal cancer. Eur J Cancer (Oxford, England: 1990) 2010, 46(16):2919-2925.
• [22]Kwak JM, Lee HJ, Kim SH, Kim HK, Mok YJ, Park YT, Choi JS, Moon HY: Expression of protein S100A4 is a predictor of recurrence in colorectal cancer. World J Gastroenterol 2010, 16(31):3897-3904.
• [23]Wang HY, Zhang JY, Cui JT, Tan XH, Li WM, Gu J, Lu YY: Expression status of S100A14 and S100A4 correlates with metastatic potential and clinical outcome in colorectal cancer after surgery. Oncol Rep 2010, 23(1):45-52.
• [24]Huang LY, Xu Y, Cai GX, Guan ZQ, Sheng WQ, Lu HF, Xie LQ, Lu HJ, Cai SJ: S100A4 over-expression underlies lymph node metastasis and poor prognosis in colorectal cancer. World J Gastroenterol 2011, 17(1):69-78.
• [25]Stein U, Burock S, Herrmann P, Wendler I, Niederstrasser M, Wernecke KD, Schlag PM: Diagnostic and prognostic value of metastasis inducer S100A4 transcripts in plasma of colon, rectal, and gastric cancer patients. J Mol Diagn 2011, 13(2):189-198.
• [26]Kang YG, Jung CK, Lee A, Kang WK, Oh ST, Kang CS: Prognostic significance of S100A4 mRNA and protein expression in colorectal cancer. J Surg Oncol 2012, 105(2):119-124.
• [27]Kho PS, Jankova L, Fung CL, Chan C, Clarke C, Lin BP, Robertson G, Molloy M, Chapuis PH, Bokey EL, et al.: Overexpression of protein S100A4 is independently associated with overall survival in stage C colonic cancer but only in cytoplasm at the advancing tumour front. Int J Colorectal Dis 2012, 27(11):1409-1417.
• [28]Giraldez MD, Lozano JJ, Cuatrecasas M, Alonso-Espinaco V, Maurel J, Marmol M, Horndler C, Ortego J, Alonso V, Escudero P, et al.: Gene-expression signature of tumor recurrence in patients with stage II and III colon cancer treated with 5'fluoruracil-based adjuvant chemotherapy. Int J Cancer 2013, 132(5):1090-1097.
• [29]Lee SJ, Choi SY, Kim WJ, Ji M, Lee TG, Son BR, Yoon SM, Sung R, Lee EJ, Youn SJ, et al.: Combined aberrant expression of E-cadherin and S100A4, but not beta-catenin is associated with disease-free survival and overall survival in colorectal cancer patients. Diagn Pathol 2013, 8(1):99. BioMed Central Full Text
• [30]Komatsu K, Kobune-Fujiwara Y, Andoh A, Ishiguro S, Hunai H, Suzuki N, Kameyama M, Murata K, Miyoshi J, Akedo H, et al.: Increased expression of S100A6 at the invading fronts of the primary lesion and liver metastasis in patients with colorectal adenocarcinoma. Br J Cancer 2000, 83(6):769-774.
• [31]Nakayama Y, Inoue Y, Minagawa N, Katsuki T, Nagashima N, Onitsuka K, Tsurudome Y, Sako T, Hirata K, Nagata N, et al.: Relationships between S-100 protein-positive cells and clinicopathological factors in patients with colorectal cancer. Anticancer Res 2003, 23(6a):4423-4426.
• [32]Stein U, Arlt F, Walther W, Smith J, Waldman T, Harris ED, Mertins SD, Heizmann CW, Allard D, Birchmeier W, et al.: The metastasis-associated gene S100A4 is a novel target of beta-catenin/T-cell factor signaling in colon cancer. Gastroenterology 2006, 131(5):1486-1500.
• [33]Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JPA, Clarke M, Devereaux PJ, Kleijnen J, Moher D: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Plos Med 2009, 6(7):e1000100.
• [34]Parmar MK, Torri V, Stewart L: Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998, 17(24):2815-2834.
• [35]Higgins JP, Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21(11):1539-1558.
• [36]Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ 2003, 327(7414):557-560.
• [37]DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986, 7(3):177-188.
• [38]Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959, 22(4):719-748.
• [39]Galbraith RF: A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med 1988, 7(8):889-894.
• [40]Begg CB, Mazumdar M: Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50(4):1088-1101.
• [41]Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315(7109):629-634.
• [42]Duval S, Tweedie R: Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000, 56(2):455-463.
• [43]Flatmark K, Pedersen KB, Nesland JM, Rasmussen H, Aamodt G, Mikalsen SO, Bjornland K, Fodstad O, Maelandsmo GM: Nuclear localization of the metastasis-related protein S100A4 correlates with tumour stage in colorectal cancer. J Pathol 2003, 200(5):589-595.
• [44]Takenaga K, Nakanishi H, Wada K, Suzuki M, Matsuzaki O, Matsuura A, Endo H: Increased expression of S100A4, a metastasis-associated gene, in human colorectal adenocarcinomas. Clin Cancer Res 1997, 3(12 Pt 1):2309-2316.
• [45]Westra JL, Schaapveld M, Hollema H, de Boer JP, Kraak MMJ, de Jong D, ter Elst A, Mulder NH, Buys CHCM, Hofstra RMW, et al.: Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients. J Clin Oncol 2005, 23(24):5635-5643.
• [46]Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, Dietrich D, Biesmans B, Bodoky G, Barone C, et al.: Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60–00 Trial. J Clin Oncol 2010, 28(3):466-474.
• [47]Barraclough R, Kimbell R, Rudland PS: Increased abundance of a normal cell mRNA sequence accompanies the conversion of rat mammary cuboidal epithelial cells to elongated myoepithelial-like cells in culture. Nucleic Acids Res 1984, 12(21):8097-8114.
• [48]Grigorian M, Ambartsumian N, Lukanidin E: Metastasis-inducing S100A4 protein: implication in non-malignant human pathologies. Curr Mol Med 2008, 8(6):492-496.
• [49]Schneider M, Hansen JL, Sheikh SP: S100A4: a common mediator of epithelial-mesenchymal transition, fibrosis and regeneration in diseases? J Mol Med 2008, 86(5):507-522.
• [50]Andersen K, Nesland JM, Holm R, Florenes VA, Fodstad O, Maelandsmo GM: Expression of S100A4 combined with reduced E-cadherin expression predicts patient outcome in malignant melanoma. Mod Pathol 2004, 17(8):990-997.
• [51]Yang H, Zhao K, Yu Q, Wang X, Song Y, Li R: Evaluation of Plasma and Tissue S100A4 Protein and mRNA Levels as Potential Markers of Metastasis and Prognosis in Clear Cell Renal Cell Carcinoma. J Int Med Res 2012, 40(2):475-485.
• [52]Emberley ED, Murphy LC, Watson PH: S100 proteins and their influence on pro-survival pathways in cancer. Biochem Cell Biol 2004, 82(4):508-515.
• [53]Salama I, Malone PS, Mihaimeed F, Jones JL: A review of the S100 proteins in cancer. Eur J Surg Oncol 2008, 34(4):357-364.
• [54]Boye K, Maelandsmo GM: S100A4 and metastasis a small actor playing many roles. Am J Pathol 2010, 176(2):528-535.
• [55]Fang W, Fan B, Xiong B: Analysis of pathological risk factors for lymph node metastasis in colorectal cancer. Hepato-gastroenterology 2009, 56(91–92):663-666.